

Conference Day 1 Agenda

27 June 2012

8.00 Registration

8.55 Chair's Opening Remarks

Harpreet Singh, Co-Founder & CSO, **Immatics Biotechnologies**

Optimizing the Effectiveness of Cancer Vaccines Using Combination Approaches

9.00 Keynote: Combination Therapies - The Next Generation of Treatment Modalities in Oncology

Axel Hoos, VP, Oncology R&D, DPU Head, Combination Therapies, **GSK**

9.30 Enhancing the Potency of Cancer Vaccines by Using Combination Approaches

Jeffrey Schlom, Chief, Laboratory of Tumor Immunology & Biology, **NCI**

10.00 Morning Refreshments & Speed Networking

11.30 Advances and Challenges in the Development of Novel Cancer Vaccines: An Update on L-BLP25, STIMUVAX

Oliver Wilbert, Senior Director Immunotherapies, **Merck Serono**

12.00 Ipilimumab/PROSTVAC Combination: Early Clinical Trial Update

James Gulley, Head, Clinical Trials Group, Laboratory of Tumor Immunology & Biology, **NCI**

12.30 PANEL DISCUSSION: When Should you Approach Other Companies for Collaboration during Development of Combination Therapies?

- Determining whether co-development is an appropriate development option
- Co-develop from the beginning or during development?

Axel Hoos, VP, Oncology R&D, DPU Head, Combination Therapies, **GSK**

Jeffrey Schlom, Chief, Laboratory of Tumor Immunology & Biology, **NCI**

1.00 Lunch & Networking

Successful Partnering Strategies

2.00 Building Additional Capabilities through Partnering Agreements

Kevin Heller, Global Lead, Oncology, Search, Evaluation & Diligence, **Bristol-Myers Squibb**

Ensuring Effective Clinical Trial Design

2.30 Sipuleucel-T: An Autologous Cellular Immunotherapy for Patients with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

Robert Tyler, Medical Director, **Dendreon**

3.00 Clinical Development of DPX-Survivac, a Multi-Cancer Vaccine Targeting the Broadly Expressed Tumor Associated Antigen Survivin

Marc Mansour, COO & CSO, **Immunovaccine**

3.30 Afternoon Refreshments & Networking

4.00 Current Challenges in Designing and Conducting Phase II Oncology Clinical Trials

Eric Leire, CEO, DanDrit Biotech

4.30 PANEL DISCUSSION: How can we Change our Early-Stage Study Design for Cancer Immunotherapies?

- How should we develop at early clinical stage? Are combined phase 1/2 studies and adaptive designs adequate?
- What are the benefits and risks of small randomized phase 2 studies?
- Should we be testing combinations right in the phase 1?
- What is the value of immunomonitoring and biomarker research in early clinical studies?

Eric Leire, CEO, DanDrit Biotech

Marc Mansour, COO & CSO, Immunovaccine

Gaining Regulatory Approval

5.00 Keynote: FDA Update on Regulatory Considerations for Development of Therapeutic Cancer Vaccines

Peter Bross, Medical Review Officer, Office of Cellular, Tissue & Gene Therapy, FDA

5.30 Chair's Closing Remarks

Conference Day 2 Agenda

28 June 2012

8.00 Registration

8.55 Chair's Opening Remarks
Vahe Bedian, Director, **AstraZeneca**

9.00 Keynote: Prioritization of Immunotherapy Opportunities and the Cancer Immunotherapy Trials Network
Martin "Mac" Cheever, Principal Investigator: **Cancer Immunotherapy Trials Network** & Member, **Fred Hutchinson Cancer Research Center**

Utilizing Biomarkers in Clinical Development

9.30 Biomarker-Guided Development of Novel Renal and Colorectal Cancer Multi-Peptide Vaccines: From Discovery to Phase III
Harpreet Singh, Co-Founder & CSO, **Immatics Biotechnologies**

10.00 Morning Refreshments & Networking

Eliciting a Stronger Immune Response

10.30 Optimizing the Use of Immunomodulators: A Poly-ICLC (Hiltonol®) Case Study
Andres Salazar, Chairman, CEO, & Scientific Director, **Oncovir**

11.00 Using New Technologies to Create a More Powerful Immune Response
Teresa Ramirez-Montagut, Research Investigator, Cancer Vaccine Initiative, **Genomics Institute of the Novartis Research Foundation**

11.30 Approaches to Improving Anti-Tumor Immunity
Tibor Keler, CSO, **Celldex Therapeutics**

12.00 Discussions: Mastermind Group

12.30 Lunch & Networking

1.30 Assessing the Immunologic and Clinical Efficacy of Dendritic Cell/Tumor Fusions as a Cancer Vaccine
David Avigan, Active Staff, Hematology-Oncology, **Beth Israel Deaconess Medical Center** & Associate Professor, **Dana Farber/Harvard Cancer Centre**

2.00 Active Immunotherapy of Cancer with Recombinant Poxviral Vaccines
Reiner Laus, President & CEO, **BN ImmunoTherapeutics**

2.30 Afternoon Refreshments & Networking

An Evidence-Based Medicine Approach

3.00 How Good is the Evidence? View from the Blue Cross Blue Shield Technology Evaluation Center
Naomi Aronson, Executive Director of the Technology Evaluation Center, **Blue Cross & Blue Shield Association**

3.30 PANEL DISCUSSION: Comparing Cancer Vaccine Treatment with Traditional Cancer Therapy

- A compelling clinical risk:benefit balance
- Handling changing standards of care during clinical trials

Vahe Bedian, Director, **AstraZeneca**

Naomi Aronson, Executive Director of the Technology Evaluation Center, **Blue Cross & Blue Shield Association**

Andres Salazar, Chairman, CEO, & Scientific Director, **Oncovir**

Manufacturing Considerations

4.00 Controlled and Consistent Sourcing of the Cellular Raw Material: Overcoming Challenges faced during Manufacturing

Michael Hanna, Founder, Chairman & CSO, **Vaccinogen**

4.30 Chair's Closing Remarks